Patent intelligence · DE
DE 69229278
HUMANISIERTER B-B10, EIN ANTI-IL-2-REZEPTOR-ANTIKÖRPER
HUMANISIERTER B-B10, EIN ANTI-IL-2-REZEPTOR-ANTIKÖRPER
Patent details — DE 69229278
- Jurisdiction
- DE
- Status
- expired
- Grant date
- Jan 5, 2000
- Expiration
- Dec 31, 2019
- Applicant
- BIOTEST PHARMA GMBH [DE]
- CPC classes
- A61K 39/ 395 A I, A61K39/395, A61P 35/ 00 A I, A61P/3500
Quick answer
DE 69229278 (HUMANISIERTER B-B10, EIN ANTI-IL-2-REZEPTOR-ANTIKÖRPER) is held by BIOTEST PHARMA GMBH [DE]. Status: expired. Granted Jan 5, 2000. Expires Dec 31, 2019 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOTEST PHARMA GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K39/395, A61P 35/ 00 A I, A61P/3500
More from BIOTEST PHARMA GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
CA 1341505
PREPARATION D'IMMUNOGLOBULINE POLYCLONALE CONTENANT DE L'IGM, AUX FINS D'ADMINISTRATION INTRAVEINEUSE, AINSI QUE SA METHODE DE FABRICATION
expired -
DK 0781560
Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse
expired -
AT E191006
MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN RHESUS D UND ZELLINIEN DIE DIESE PRODUZIEREN
expired
Frequently asked questions
What is US patent 69229278?
DE 69229278 (HUMANISIERTER B-B10, EIN ANTI-IL-2-REZEPTOR-ANTIKÖRPER) is held by BIOTEST PHARMA GMBH [DE]. Status: expired. Granted Jan 5, 2000. Expires Dec 31, 2019 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns DE 69229278?
BIOTEST PHARMA GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does DE 69229278 expire?
Our index shows an expiration date of Dec 31, 2019 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.